US Federal House Bill HB4668

US Federal 2025-2026 Regular Session

• Introduced: 7/23/25
• Refer: 7/23/25

Caption

End the Vaccine Carveout Act

Summary

HB4668, titled the End the Vaccine Carveout Act, would substantially rewrite federal law governing vaccine injury claims and certain public-health liability protections. The bill amends the Public Health Service Act to eliminate the current liability shield for vaccine manufacturers and administrators, allowing people alleging vaccine-related injury or death to bring civil lawsuits in state or federal court. It also changes the National Vaccine Injury Compensation Program so that filing a claim there would no longer be the exclusive or primary route for recovery, and it removes several existing procedural limits and election rules that currently force claimants to choose between the compensation program and civil litigation. The bill also repeals multiple provisions tied to the vaccine injury compensation framework, including sections governing election of remedies, standards of responsibility, and trial procedures. It would revise limitations periods so that claims under the compensation program could be filed at any time, and it would apply those changes retroactively as if they had been part of the original statute. In addition, the bill narrows the federal Public Readiness and Emergency Preparedness-style liability protections by excluding COVID-19 vaccines from the definition of “covered countermeasure,” while leaving other emergency-use products and respiratory protective devices within that definition.

Impact

If enacted, the bill would significantly alter the legal landscape for vaccine-related injury and death claims by opening the door to ordinary tort litigation against vaccine manufacturers and administrators and by weakening the exclusivity of the federal compensation program. It would amend key sections of the Public Health Service Act, including provisions in the National Vaccine Injury Compensation Program and the federal liability framework for covered countermeasures, and would likely increase exposure to lawsuits, change claims-handling practices, and affect how vaccine-related compensation is pursued in both state and federal courts.

Sentiment

Based on the bill title, sponsors, and the absence of recorded committee debate or votes in the provided materials, the bill appears to be supported by members who favor removing vaccine liability protections and skeptical of current federal vaccine policy. The introduction by a large group of Republican members suggests a partisan and ideologically driven effort to roll back existing protections. No contrary committee sentiment is available in the record provided, but the measure’s sweeping changes indicate it is likely to be controversial.

Contention

The main point of contention is the bill’s elimination of the liability shield and the Vaccine Injury Compensation Program’s current election-of-remedies structure. Supporters appear to argue that vaccine manufacturers should face ordinary civil liability and that claimants should have direct access to court, while opponents would likely contend that removing these protections could undermine vaccine availability, increase litigation, and destabilize the compensation system designed to handle vaccine injury claims. Another likely flashpoint is the bill’s specific exclusion of COVID-19 vaccines from federal countermeasure protections, which would treat those vaccines differently from other emergency-use products.